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Summary 
A recent multi-centre, double blind, randomised, placebo controlled trial has demonstrated that 
administration of betamethasone to women with threatened preterm delivery at 34 to 36 weeks' of 
gestational age reduces the risk of neonatal respiratory morbidity. There is, however, no long term 
outcome data on the children and we believe that it is biologically plausible that this treatment may 
cause long term harm through effects on the infant's brain. Given this, we argue that steroids should 
not be used in the context of late preterm delivery until evidence of long term safety is available. This 
example illustrates some strengths and weaknesses of using "levels of evidence" to grade the 
empirical support for making clinical decisions.  
 
 
 
One of the major advances in perinatal medicine in the last 30 years has been the administration of 
synthetic glucocorticoids to mothers who are likely to deliver at extreme preterm gestational ages, 
and this intervention clearly reduces perinatal mortality and severe morbidity.
1
 A recent multi-
centre, double blind, randomized controlled trial compared the effects of betamethasone versus 
placebo among women presenting between 34 and 36 weeks of gestational age with a high 
probability of delivery.
2
 The primary outcome was need for respiratory support three days after 
delivery. The rate was 11.6% in steroid treated children and 14.4% with placebo, yielding a number 
needed to treat of 35 (95% CI 19 to 259). In addressing the question of whether this trial justifies 
immediate incorporation of glucocorticoids into the management of threatened delivery at 34 to 36 
weeks, we need to consider both the science of glucocorticoids in pregnancy, and the science of 
clinical trials. 
 
Physiologically, the fetus prepares for birth near term by an increased production of cortisol from 
the fetal adrenal. The glucocorticoids employed therapeutically to accelerate fetal lung maturation 
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are betamethasone and dexamethasone. The choice is purposeful as both are resistant to 11β-
hydroxysteroid dehydrogenase-2 (11β-HSD-2), 
3
 an enzyme which is highly expressed in the placenta 
and which limits transplacental passage of maternal cortisol, by converting it to inactive metabolites. 
Consequently, steroids which are metabolised by 11β-HSD-2 (such as cortisol, hydrocortisone and 
prednisolone) cannot cross the placenta whereas 11β-HSD-2-resistant steroids can. Importantly, the 
fetal brain has high levels of expression of 11β-HSD-2, especially in areas which undergo rapid 
growth in the third trimester (e.g. the cerebellum).
4
 As a result, the brain is relatively protected from 
the effects of the physiological rise in endogenous cortisol in late gestation.
5
 It follows, however, 
that maternally administered betamethasone or dexamethasone near term will both cross the 
placenta and activate brain glucocorticoid receptors due to the resistance of these drugs to 
metabolism by 11β-HSD-2. Hence, betamethasone and dexamethasone will cause  un-physiological 
activation of glucocorticoid receptors in the fetal brain near term. 
 
Should we be concerned? There are a number of observations that suggest we should. First, it has 
been shown 11β-HSD-2 resistant glucocorticoids inhibited normal cerebellar growth when 
administered to neonatal mice
6
 and had profound and long lasting epigenetic effects on the brain of 
fetal guinea pigs following maternal administration in late gestation.
7
 Second, the one study that 
previously examined long term outcomes following betamethasone in late pregnancy (given prior to  
pre-labour caesarean section at 37 or 38 weeks' of gestational age) demonstrated that 
glucocorticoid-exposed children were twice as likely to be identified as being in the lowest 
achievement group at school compared with the control group (17.7% vs 8.5%, RR 2.1; 95% CI, 1.1-
3.7).
8
 Interestingly, the same trial demonstrated no long term benefit of steroids. Part of the 
motivation for the original trial had been that prevention of short term respiratory morbidity around 
the time of birth may reduce the risk of respiratory disease in later childhood. However, the long 
term follow up study demonstrated no such benefits. Hence, the justification for glucocorticoids 
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prior to term pre-labour caesarean section is wholly based on reducing the risk of short term 
complications. 
 
A number of studies have compared longer term follow up (in children
1
 and adults
9
) in those 
exposed to antenatal glucocorticoids and placebo controls from the original RCTs of glucocorticoids 
in women presenting with threatened preterm birth. However, these studies generally assessed the 
effects of steroid exposure at earlier gestational ages. Overall, these results are reassuring and 
support the use of steroids in the management of preterm birth prior to 34 weeks.
1
 However, the 
apparent long term safety of steroids following exposure at more extreme degrees of prematurity 
does not confirm their safety at later gestational ages. Potential direct harmful effects of steroids on 
the brain could be masked by the generally protective effect of improved neonatal cardiorespiratory 
function and reduced risks of specific acute perinatal complications, such as intra-ventricular 
haemorrhage. Moreover, activation of the glucocorticoid receptor by steroids is regulated by 
multiple aspects of the cellular and physiological context, termed "context-driven plasticity".
10
 It is 
possible – indeed likely – that the effect of a given concentration of a given steroid may differ at 
different gestational ages due to the multiple factors that change with advancing gestational age and 
the complex regulation of glucocorticoid receptor mediated responses. 
 
In the context of extreme preterm birth (e.g. 24-28 weeks gestational age), the balance of risks and 
benefits favours the use of glucocorticoids, as they have clearly been shown to prevent death, and 
severe adverse outcome in the short and long term.
1
 However, in our view, the case has not been 
established that the balance of risks and benefits favours their use after 33 weeks of gestational age. 
We know that use of steroids in women with threatened delivery at 34 to 36 weeks means that 35 
children need to be treated to prevent one child requiring respiratory support three days after 
delivery. What we do not know is the long term effects of fetal exposure to these drugs at this 
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gestational age, i.e. whether the prevalence or severity of long term adverse effects – if there are 
any – outweigh the known benefit.  
 
This example also illustrates a series of key points about randomized controlled trials in perinatal 
medicine: (i) there are multiple outcomes which may be affected by an intervention, (ii) the effect of 
an intervention might differ proportionally and directionally for different outcomes, (iii) the level of 
evidence around different effects may differ. In the case of late preterm glucocorticoids, their 
beneficial short term effect is supported by level 1 evidence. In contrast, the potential for adverse 
effects on the fetal brain is largely based on level 5 evidence, i.e. expert opinion and basic research.  
A relative lack of evidence on rare and long term outcomes is a general feature of trials, and reflects 
some practical realities: trials are expensive and the larger they are and the longer the follow up, the 
more expensive the trial. Consequently, trials are biased to be powered for outcomes which are 
common and occur in the short term. In contexts such as extreme preterm birth and cancer, the 
clinically most important outcomes, such as death, may be common and occur in the short term. 
However, in many other contexts, including late preterm delivery, common and short term 
complications are generally not severe, and the most important outcomes may be rare and/or long 
term, including harm done by the intervention. A danger of RCTs in obstetrics is that trials may not 
be funded or powered to detect long term adverse outcomes in children. 
 
Ideally, the absence of level 1 evidence for all of the major outcomes of interest would not be a 
problem. The lack of information on long term outcomes, or underpowered analyses leading to wide 
confidence intervals, would be interpreted as indicating that there is no accurate information about 
whether these outcomes are affected by the intervention, and the absence of evidence would be a 
cause for concern. However, it has been suggested that the six most dangerous words in evidence-
based medicine are: “there is no evidence to demonstrate”.
11
 If the “absence of evidence” is 
conflated with “evidence of absence” we will be misled. The correct summary of using 
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glucocorticoids at 34 to 36 weeks is that there is evidence of short term benefit but an absence of 
evidence of long term safety. But there are those who might state that there is evidence of short 
term benefit and no evidence to demonstrate long term harm. The different wording yields a 
profound difference in inference.  
 
Randomized trials have had a hugely positive effect on the practice of obstetrics and paediatrics. The 
strength of trials is that this study design has the highest internal validity, all other things being 
equal. But crucially, we cannot assume no effect for questions where there are limited or no data. 
Therefore, when we assess the evidence base we must consider all the issues. The problem is not 
trials. The problem is a simplistic approach to a complex question. Labelling evidence on the basis of 
study design alone, without reference to statistical power, particular attention to adequate length of 
follow up, harm, external validity, or biological plausibility is treating a complex question in a 
simplistic manner. We ignore complexity at our peril or, rather, at the peril of our patients. 
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